Novo Nordisk Buys Akero: Betting Big on Liver Disease

Novo Nordisk Buys Akero: Betting Big on Liver Disease

A $5.2B deal adds a Phase 3 MASH candidate and broadens Novo’s cardiometabolic platform beyond GLP‑1s. Novo Nordisk’s agreement to acquire Akero Therapeutics for up to $5.2 billion is more than bo...